Impact of Reimbursement for Biomarker Testing on Clinical Practice

Geoff Oxnard, MD
Thoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Lauren Ritterhouse, MD, PhD
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Related Articles
Building an Award-Winning Local Navigator Network
October 2019 Vol 10, No 10
An Interview with Donna Moore Wilson, RN, MSN, CBCN, of the Virginia Cancer Patient Navigator Network
The CAPE Initiative: Developing Meaningful Educational Materials to Elevate Quality of Life for Patients with Lung Cancer
July 2019 Vol 10, No 7
An Interview with Cheryl Bellomo, MSN, RN, OCN, ONN-CG, and Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T)
An Interview with Gregory C. Simon, JD, About the Biden Cancer Initiative’s Strategies to Improve Cancer Care
Kristin Siyahian
|
March 2019 Vol 10, No 3
Last modified: January 16, 2019

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code